**Inogen (INGN) experienced a significant increase in stock price, rising 6.9% to close at $6.80 in the latest trading session. This surge occurred on elevated trading volume, reversing a stagnant period over the past month. The boost follows a “Buy” rating from Freedom Broker, which also set a positive price target, generating renewed investor interest.**
**Inogen, known for producing oxygen concentrators for patients with chronic respiratory conditions, is anticipated to report a quarterly loss of $0.24 per share, marking a 4% year-over-year change. Revenue expectations stand at $82.4 million, reflecting a marginal increase of 0.2% from the previous year. The company’s recent board appointments and governance improvements have also been noted as factors enhancing strategic alignment.**
**As of now, Inogen holds a Zacks Rank of #3 (Hold), while competitor PROCEPT BioRobotics Corporation (PRCT) dropped 2.5% to $23.19, with a consensus EPS estimate decline of 16.7% for its upcoming report.**
